PURE Bioscience, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
PURE Bioscience, Inc. (PURE) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 333.33 thousand shares for the 3-month period ending 2021-10-31, per its 10-Q filed 2021-12-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2021-12-15
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2021-10-31 was 333.33K shares, a 33.33% decline year-over-year.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2021-07-31 was 6.24M shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2021-04-30 was 0.00 shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2021-01-31 was 0.00 shares.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2021 was 6.74M shares, a 1585.09% increase from fiscal 2020.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2020 was 400.00K shares, a 0.00% change from fiscal 2019.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2019 was 400.00K shares, a 6.67% increase from fiscal 2018.
- PURE Bioscience, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2018 was 375.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2021-10-31 | 333.33K shares 10-Q · filed 2021-12-15 | 6.57M shares derived: sum of 2 quarters · filed 2021-12-15 | 6.57M shares derived: sum of 3 quarters · filed 2021-12-15 | 6.57M shares derived: sum of 4 quarters · filed 2021-12-15 | |
| 2021-07-31 | 6.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-28 | 6.24M shares derived: sum of 2 quarters · filed 2021-10-28 | 6.24M shares derived: sum of 3 quarters · filed 2021-10-28 | 6.74M shares 10-K · filed 2021-10-28 | |
| 2021-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-15 | 0.00 shares derived: sum of 2 quarters · filed 2021-06-15 | 500.00K shares 10-Q · filed 2021-06-15 | 500.00K shares derived: sum of 4 quarters · filed 2021-06-15 | |
| 2021-01-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-15 | 500.00K shares 10-Q · filed 2021-03-15 | 500.00K shares derived: sum of 3 quarters · filed 2021-03-15 | 500.00K shares derived: sum of 4 quarters · filed 2021-03-15 | |
| 2020-10-31 | 500.00K shares 10-Q · filed 2020-12-15 | 500.00K shares derived: sum of 2 quarters · filed 2020-12-15 | 500.00K shares derived: sum of 3 quarters · filed 2020-12-15 | 500.00K shares derived: sum of 4 quarters · filed 2020-12-15 | |
| 2020-07-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-08 | 0.00 shares derived: sum of 2 quarters · filed 2020-10-08 | 0.00 shares derived: sum of 3 quarters · filed 2020-10-08 | 400.00K shares 10-K · filed 2020-10-08 | |
| 2020-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-11 | 0.00 shares derived: sum of 2 quarters · filed 2020-06-11 | 400.00K shares 10-Q · filed 2020-06-11 | ||
| 2020-01-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-03-12 | 400.00K shares 10-Q · filed 2020-03-12 | |||
| 2019-10-31 | 400.00K shares 10-Q · filed 2019-12-13 | ||||
| 2019-07-31 | 400.00K shares 10-K · filed 2020-10-08 | 206.25K shares 10-K · filed 2019-10-30 | |||
| 2018-07-31 | 375.00K shares 10-K · filed 2019-10-30 | ||||
| 2015-07-31 | 1.72M shares 10-K · filed 2015-10-28 | ||||
| 2014-07-31 | 1.21M shares 10-K · filed 2015-10-28 |